medigraphic.com
SPANISH

Salud Mental

ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2011, Number 2

<< Back Next >>

Salud Mental 2011; 34 (2)

Costo-efectividad de intervenciones para esquizofrenia en México

Cabello RH, Díaz CL, Arredondo A
Full text How to cite this article

Language: Spanish
References: 24
Page: 95-102
PDF size: 109.60 Kb.


Key words:

Schizophrenia, cost-effectiveness, readmitted.

ABSTRACT

The World Health Organization estimates that the expense of attending mental illness problems in developed countries amounts to 3-4% out of the total GDP. The public expense for hospitalization of patients diagnosed with schizophrenia was three times higher in patients who decide to leave the treatment than those who continue with it; ambulatory patients amount to almost the same figures in public expenses whether they decide to continue the treatment or not.
In the USA, there are 87 000 people hospitalized due to schizophrenia every year, which represent 93 000 hospital days with a cost of about 806 billion dollars a year; to stop patients from leaving the treatment, however, would cut the number of acute cases 12.3% and hospitalizations 13.1%. These two reductions would cut down the expenses in Medicaid as much as 106 million dollars.
According to data gathered by the Organization for the Economical Cooperation and Development for Germany, the expense in mental health accounts for 10% of total health expenses, being schizophrenia, depression and anxiety the most costly illnesses. Finland doubled the expenses to attend those who suffered mental illnesses between 1990 and 2003. The total annual expenses for the treatment of schizophrenia in Latin American and Caribbean countries accounts for 1.81%, for Africa 0.47%, for Europe 1.32% and for southern Asia 0.52 in millions of dollars per every million people.
In Mexico, a first estimate, based on the demand and the amount of money destined to attend this problem by every health institution, it was concluded that the average annual expenses in medical attention for schizophrenia was US97.54 per person. The Health Sector reports that the cost for a psychiatric evaluation or psychotherapy amounts to US1.42 and the estimated annual cost for the treatment of schizophrenia in a public institution amounts to somewhere between US60.34 and US2,186.83; all this would depend on the haloperidol or clozapine drug. In a private institution, the cost for a psychiatric evaluation is US63.44 and the annual estimated cost is somewhere between US1,695.79 and US5,988.58 including treatments with the aforementioned drugs.
The cost-effectiveness analysis is a method which indentifies, quantifies and values the expenses of two or more alternatives of sanitary intervention available at the time to reach certain objectives. This will be possible as long as the effects are channeled to the same class of effects. The measure of the analysis summary concerning cost-effectiveness is the ratio cost-effectiveness which allows comparison of different action alternatives, identifying two types of indicators: average cost and increased cost.
Regarding the methodological procedures, the research project was based in a length and descriptive study, though not statistical. It was designed to carry out an analysis of cost-effectiveness in the alternatives of treatment for patients who were diagnosed with schizophrenia at the Fray Bernardino Psychiatric Hospital. This study allowed the identification and quantification of costs of the demand, the treatment, hospitalization, and the ambulatory services. The effectiveness of the alternatives in treatment studied is measured in terms of the readmitted.
Four non-statistical samples were taken of clinical files out of each studied service. External Consultation: 50 clinical files, 15 were discarded for not being diagnosed with schizophrenia; the other 35 were followed and analyzed for six months. Day Hospital: 65 files of the total of patients diagnosed with schizophrenia, 12 were discarded for being diagnosed differently. Therapeutic clinical adherence (TAC): a sample of 85 files of patients diagnosed with schizophrenia was taken. Patients with membership to ISSSTE diagnosed with schizophrenia who came out of hospitalization between June-October 2008 were followed during a period of six months in order to measure the readmitted to hospitalization; 67 patients were registered.
The costs of personnel (doctor, nurses, social service, and psychology and hygiene staff) were obtained out of the coefficient of the total annual salary between the annual working day in minutes for the time destined to attention of each patient. The costs for catering and laundry were calculated directly. The laboratory cost was obtained taking into account cost-time destined to the study of administrative personnel, technicians and supervision, as well as materials and the necessary equipment. The indirect costs (security, hygiene, water, electric power, and municipal and biological waste) were obtained dividing the total annual costs in the average annual number of patients who needed hospitalization; this was done taking into account that the daily average in occupation is 296 patients. The external consultation was excluded for being deemed unimportant in terms of consumption. Analysis: descriptive statistics. Cost-effectiveness analysis.
With respect to the main findings, the hospitalization costs are: emergency room US136.00, intensive care US162.72, and continuous hospitalization US68.83. The cost of day hospital is US34.57, US68.91 in TAC and external consultation US9.67. The semester consultation for patients undergoing external consultation, day hospital and TAC received 2.3, 23.5 and 7.5 each one. The readmitted in ambulatory services are 8.5%, 7.5%, and 5.8% for external consultation, day hospital, and TAC. The hospitalization days for patients who were readmitted due to an increase in symptoms was 42.5, 12.5, and 25 days in average for external consultation, day hospital and TAC. The effectiveness coefficient indicates that avoiding a readmitted to external consultation, day hospital, TAC and external consultation at ISSSTE amounted to US15.26, US518.84, US499.23 and US16.37 accordingly. The cost of making use of an additional hospital unit during the day is US1321.41; it amounts to US1166.31 for therapeutic care and US17.79 at ISSSTE.
According to the main results, the costs for medical attention through the system of cascade primary costs differ too much when compared to the unitary costs published in the Diario Oficial; the ambulatory costs are very different in terms of costs but they show very similar results. The difference between the costs for attending patients diagnosed with schizophrenia is due to the number of patients and the personnel assigned to the area.
These results are influenced by the number of semester consultations: 23.5 times in day care hospitalization against the 7.5 and 2.3 times in average of TAC and external consultation accordingly. The average rate of avoided readmitted is low in external consultation compared to the other three alternatives; this rate is affected by the largest number of people who abandoned TAC, which could empirically be explained by the need of the patient to buy his medication.
Upon making a comparison of the costs of the alternatives of integral treatment for schizophrenia in the Fray Bernardino Psychiatric Hospital, we found that the average cost for external consultation is much clearer in terms of cost-effectiveness than day hospital and TAC; this means that the first option is much more effective and less money is required than the other two. Even though external consultation registers a very high rate of abandonment in terms of treatment by the patients, it still shows to be more effective. It is also slightly more effective than external consultation at ISSSTE; this is to say that if we only consider the effectiveness based on how much we avoid readmitted, it would be much more appropriate for patients who attend external consultation to be given the necessary medication and in doing so reducing the costs of day care hospitalization and TAC.
The increased cost shows that avoiding an admitted to day hospital results in a cost of about US1321.41 which is almost the same as readmitted a patient attending external consultation whose symptoms have become more acute, and much more expensive than the total cost of attending that patient in that service over six months.
The cost for avoiding a readmitted in TAC is US1166.31 whereas the cost for avoiding a readmitted in ISSSTE is US17.79 the strategy should be targeted to providing the necessary medication for patients who are attending external consultation.


REFERENCES

  1. Organización Mundial de la Salud. Invertir en salud. Ginebra: 2004. http://www.who.int/mental.health. Revisado última vez marzo 2010.

  2. Gilmer TP, Dolder CR. Adherente to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-699.

  3. Marcus SC, Olfson M et al. Outpatient antipsychotic treatment and inpatient cost of schizophrenia. Schizophrenia Bull 2008;34(1):173-180.

  4. Organization for Economic Co-operation Development. Policy Brief; 2008 November.

  5. World Health Organization. Disease control priorities related to mental, neurological, developmental, and substance abuse disorders. Geneva: 2006.

  6. Tacchi MJ, Scott J. Mejoría de la adherencia terapéutica en esquizofrenia y trastorno bipolar. Madrid: Ed. Wiley; 2007.

  7. Lacro JP, Dunn LB, Dolder CR, Leckband SG. Prevalence of and risk factors for medication non-adherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.

  8. Thieda P, Beard S et al. An economic review of compliance with medication therapy in therapy in Treatment of schizophrenia. Psych Service 2003;54(4):508-516.

  9. Svarstad BL, Shireman TI et al. using drug claims data to assess the relationship of medication adherence with hospitalization and cost. Psych Service 2001;52:805-811.

  10. Knapp M, King D et al. Non-adherence to antipsychotic medication regimens: Associations with resources use and costs. Br J Psych 2004;184:509-516.

  11. Bustillo JR, Lauriello J, Horan WP et al. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 2001;158(2):163-175.

  12. Rascón R, Arredondo A, Tirado L, López M. Una aproximación al costo de las enfermedades mentales en México: depresión y esquizofrenia. Salud Mental 1998;21(1):43-47.

  13. Secretaría de Salud. Programa de Acción Específico 2007-2012 atención en salud mental. México: 2008.

  14. Lara-Muñoz M, Robles-García R, Orozco R, Saltijeral M et al. Estudio costo-efectividad del tratamiento de la esquizofrenia en México. Salud Mental 2010;33:211-218.

  15. Drummond M, O Brian B. Métodos para la evaluación económica de los programas de asistencia sanitaria. Segunda edición. Madrid: Ed. Díaz de Santos; 2001.

  16. Temes JL, Mengilbar M. Gestión hospitalaria. Segunda edición. Ed. Mc Graw Hill; 2007.

  17. Gimeno JA. Economía de la salud; instrumentos. Primera edición. Madrid: Ed. Díaz de Santos; 2003.

  18. Consejo Nacional de Población. República Mexicana: Indicadores demográficos, 1990-2050. En: www.conapo.gob.mx

  19. Medina-Mora M, Lara Muñoz C, Benjet C. Blanco Jaimes J et al. Prevalencia de trastornos mentales y uso de servicios: Resultados de la encuesta nacional de epidemiología psiquiátrica en México. Salud Mental 2003;26(4):1-16.

  20. Diario Oficial de la Federación. Acuerdo por el que se aprueban costos unitarios por nivel de atención médica para el año 2009. Secretaria de Gobernación. México: 6 marzo 2009.

  21. Reynales-Shigematsu LM. Costo de la atención médica atribuible al consumo de tabaco en el IMSS. Salud Pública México 2006;48(Supl 1):190-200.

  22. García Aguirre JL, Freyre Galicia J. Costos de tratamiento farmacológico de la esquizofrenia paranoide y su impacto en la economía familiar. Psiquis 2006;15(4):89-94.

  23. Stephen A, Knapp M, François C et al. Release in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-351.

  24. Linn MW, Coffey EM et al. Day treatment and psychotropic drug in the aftercare in schizophrenia patients. Arch Gen Psychiatry 1979;158:24-7.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Salud Mental. 2011;34